Notable News to Focus: ClearPoint Neuro (NASDAQ:CLPT)
ClearPoint Neuro (NASDAQ:CLPT) changed -0.57% to recent value of $3.51. The stock transacted 30701 shares during most recent day however it has an average volume of 51.78K shares. It spotted trading -44.54% off 52-week high price. On the other end, the stock has been noted 74.63% away from the low price over the last 52-weeks.
On April 17, 2020, ClearPoint Neuro (NASDAQ:CLPT) is pleased to revealed that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro’s Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics (PTC), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. He succeeds Marcio Souza, who joined ClearPoint Neuro’s Board as PTC’s representative in connection with PTC’s May 2019 equity investment in ClearPoint Neuro. Mr. Souza, who resigned from his position as PTC’s Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuro’s Board as an independent member.
Prior to joining PTC, Dr. Klein served in several executive positions with BioElectron Technology Corporation (BioElectron), most recently as BioElectron’s Chief Executive Officer and a Director prior to its acquisition by PTC in 2019. Dr. Klein has a BA from the University of Pennsylvania, an MD from Yale University School of Medicine and an MS in epidemiology from the University of Washington School of Public Health.
We are thrilled by the addition of Matt to our board and the contributions he will make to our company and culture, commented Joe Burnett, President and CEO. As a patient-centric company, adding an established physician, scientist and leader to our board will improve our ability to evaluate new technologies and partnerships.
CLPT has a gross margin of 65.80% and an operating margin of -41.10% while its profit margin remained -49.40% for the last 12 months. Its earnings per share (EPS) expected to touch remained 25.30% for this year while earning per share for the next 5-years is expected to reach at 30.00%.
The company has 17.87M of outstanding shares and 8.45M shares were floated in the market. According to the most recent quarter its current ratio was 2.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of -0.60% from the mean of 20 days, -20.35% from mean of 50 days SMA and performed -18.91% from mean of 200 days price. Company’s performance for the week was 3.85%, 4.10% for month and YTD performance remained -26.88%.